Adverse effect · Sermorelin

How common is safety in adults with Sermorelin?

C
Grade C — weak human evidenceCompounding-era use · effect size: not measurable · adverse
Short answerWeak human evidence. Compounding-era use: enough to be interesting, not enough to count on. Where an effect is seen it is no measurable effect, or none yet shown. Long clinical familiarity from the paediatric era and compounded adult use; no modern controlled long-term dataset.

What the studies show

Long clinical familiarity from the paediatric era and compounded adult use; no modern controlled long-term dataset.

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

In context

Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone — the active fragment. It was FDA-approved in 1990 as Geref for diagnosing growth-hormone deficiency in children, and the brand was withdrawn in 2008 for commercial reasons, not safety. It reliably raises growth hormone and IGF-1. The adult anti-ageing and body-composition claims rest on small open-label studies, not randomised trials.

Sermorelin is withdrawn (us brand). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Sermorelin proven to cause safety in adults?
No. The human evidence is weak (Compounding-era use); LYO grades it C.
What studies are behind the grade?
Long clinical familiarity from the paediatric era and compounded adult use; no modern controlled long-term dataset.
Is Sermorelin approved for this?
No. Sermorelin is withdrawn (US brand); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Sermorelin

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →